AdhexPharma
AdhexPharma is a France-based pharmaceutical CDMO specializing in transdermal patches and oral films, offering end-to-end development, manufacturing, analytical, and licensing services to blue-chip pharmaceutical companies and innovative start-ups across global markets.
- Company typePrivate
- Founded2007
- HeadquartersParis, France
- Headcount51–100
- GTM typeB2B
- OfferingServices
What AdhexPharma does
AdhexPharma is a privately held, France-headquartered pharmaceutical Contract Development and Manufacturing Organization (CDMO) that specializes in transdermal patches and oral films. The company delivers end-to-end services from drug concept through formulation development, analytical services, cGMP-compliant manufacturing, and licensing, serving both blue-chip pharmaceutical companies and innovative start-ups. Its technology platform centers on four proprietary drug delivery systems: Transfilm® (transdermal patches), Rapidfilm® (orodispersible oral films for gastrointestinal absorption), Mucofilm® (oromucosal buccal/sublingual films with limited industrial-scale competition), and Impregnated Matrix Patch technology. AdhexPharma currently manufactures eight approved products representing approximately 100 million units per year, with stated annual production capacity of 180 million units.
The business operates across four service lines: Contract Development, Contract Manufacturing, Analytical Services, and Licensing of branded products such as Nicopatchlib® (nicotine patch), Rivendo® (rivastigmine patch), and Zeqmelit® (dexamethasone oral film). Revenue is generated through project-based, quote-based B2B contracts — no standardized pricing is publicly disclosed — and the company emphasizes its ability to handle highly potent APIs, narcotics, and hormones under EMA, FDA, ISO 13485, 21 CFR Part 11, and 21 CFR Part 820 compliance. The Franco-German operational footprint combines French manufacturing (Paris HQ, Chenôve production) with German R&D and production acquired via Labtec GmbH (from tesa SE/Beiersdorf) in September 2022 and earlier AMW assets, creating a complementary cross-border CDMO platform. The company is owned by Burgundy Ventures, a French industrial holding, and was founded in 2007 to acquire the transdermal patch unit of Solvay in France. AdhexPharma is currently constructing a new 8,000 m² facility in Chenôve with completion targeted for end of 2025 and was prequalified for the France 2030 'Industrialization and Health Capacities' program.
AdhexPharma firmographics
Firmographics- Name
- AdhexPharma
- Legal name
- ADHEXPHARMA (500 806 633 RCS Paris)
- Website
- https://adhexpharma.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- AdhexPharma is a France-based pharmaceutical CDMO specializing in transdermal patches and oral films, offering end-to-end development, manufacturing, analytical, and licensing services to blue-chip pharmaceutical companies and innovative start-ups across global markets.
- Ownership category
- akta.pro rank
AdhexPharma industry classification
Industry- Product category
- Pharmaceutical CDMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where AdhexPharma is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices4 records
Markets served
AdhexPharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Development Services: Full-service contract development from feasibility assessment through product development and clinical trial supply manufacturing to formulation transfer for commercial production
- Contract Manufacturing Services: cGMP-compliant manufacturing of transdermal patches and oral films for clinical trials and commercial markets. Handles entire supply chain from purchasing to packaging and storage.
- Licensing: Licensing opportunities for innovative products including Lidocaine/Prilocaine Impregnated Matrix Patch, Nicotine Matrix Patch (Nicopatchlib®), Rivastigmine Patch (Rivendo®), and Dexamethasone Oral Film (Zeqmelit®)
- Analytical Services: Comprehensive analytical support including method development, validation, transfer, quality control testing, release testing, stability storage and testing, with expertise in planar dosage forms analytics for patches and oral films
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
AdhexPharma product offering
Product offeringCore offering
AdhexPharma is a full-service pharmaceutical CDMO specializing in the development and manufacturing of transdermal patches and oral films. The company provides end-to-end services from drug concept to market, including contract development, cGMP-compliant contract manufacturing, analytical services, and licensing of proprietary drug delivery technologies (Transfilm®, Rapidfilm®, Mucofilm®) and finished products (Nicopatchlib®, Rivendo®, Zeqmelit®). AdhexPharma serves both blue-chip pharmaceutical companies and innovative start-ups, manufacturing approximately 180 million units annually across 8 approved products.
Product overview
AdhexPharma is a full-service CDMO (Contract Development and Manufacturing Organization) specializing in transdermal patches and oral films. The company offers a portfolio of proprietary drug delivery technologies including Rapidfilm® (orodispersible oral films for gastrointestinal absorption), Mucofilm® (oromucosal films for buccal/sublingual delivery), Transfilm® (transdermal patches), and Impregnated Matrix Patches. Beyond its own technologies, the company manufactures and licenses several approved products including Nicopatchlib® (nicotine patch), Rivendo® (rivastigmine patch), and Zeqmelit® (dexamethasone oral film). AdhexPharma provides integrated services spanning contract development, contract manufacturing, analytical services, and licensing, handling all steps from drug concept through commercial production.
Differentiator
Problem solved
Functional benefit
Brands
- Mucofilm®: Oral film technology designed for buccal or sublingual use with better absorption of the active ingredient and protection against copying. Can be designed for local treatment within the oral cavity or for systemic treatment of the whole body.
- Rapidfilm®
- Transfilm®
- Nicopatchlib®
- Rivendo®
- Zeqmelit®
- Lidocaine/Prilocaine Impregnated Matrix Patch
Products and services
- Rapidfilm®
Quantifiable outcome
- Manufacturing over 100 million units per year across 8 approved products
- +3 more outcomes
Companies that use AdhexPharma
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles1 record
AdhexPharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
AdhexPharma partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Studio MustardminorArchitect firm for the new 8000m² facility in Chenôve, France. Contributing architectural innovation with tertiary spaces constructed with wooden framework.
- CroqüsminorEnergy efficiency consultants for the new Chenôve facility. Ensuring the building meets the highest standards of sustainable construction and environmental regulations (RE2020).
- France 2030coreAdhexPharma was selected as a prequalified candidate for the 'Industrialization and Health Capacities France 2030' project, underscoring the company's central role in the future of pharmaceutical manufacturing for essential and innovative medications.
- Groupe GuitonminorEngineering and building contractor for the construction of the new 8000m² state-of-the-art facility in Chenôve, France. The partnership supports AdhexPharma's facility expansion plans.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
AdhexPharma competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Lonza is one of the world's largest CDMOs across small molecules, biologics, and drug product services; it competes for broader CDMO engagements and increasingly for specialty dosage forms, including transdermal.
- Recipharm: Recipharm is a European-headquartered contract developer and manufacturer of pharmaceuticals with broad drug product capabilities, representing a wider-incumbent comparable in the European CDMO market.
- Catalent (Novo Holdings): Catalent is a large global CDMO with a meaningful softgel, oral, and specialty drug delivery franchise; while not patch-specialist, it competes for adjacent CDMO work and represents the broader incumbent competitive backdrop.
Direct peers
- Tapemark: Tapemark is a US-based contract developer and manufacturer of transdermal patches, topical formulations, and oral thin films, directly comparable to AdhexPharma's CDMO offering in patches and films.
- Corium (Gurnet Point Capital): Corium is a specialty transdermal and oral film CDMO focused on innovative drug delivery, including patches and dissolvable films, overlapping directly with AdhexPharma's technology and customer base.
- Noven Pharmaceuticals: Noven (a Hisamitsu subsidiary) specializes in transdermal drug delivery systems and is a longstanding direct peer in patch development and manufacturing, serving similar pharma clients with comparable dosage forms.
- LTS Lohmann Therapie-Systeme: LTS is a leading global CDMO focused exclusively on transdermal patches and oral thin films, making it the closest direct competitor to AdhexPharma in both technology and customer base (pharma innovators seeking patch/film development and manufacturing).
Emerging players
- Vektor Pharma: Vektor Pharma is a German transdermal patch development specialist focused on innovative TDDS, comparable in geography and product focus to AdhexPharma's German operations via Labtec.
- AavantiBio / Osmotica Pharmaceutical (oral film): Osmotica-affiliated entities have developed oral thin film products (e.g., ZolpiMist-style films), making them an emerging/specialty player in the orodispersible film space where AdhexPharma also competes.
- ARx Solutions: ARx Solutions is a US-based specialty CDMO with expertise in transdermal and topical drug delivery, an emerging specialist peer in the same niche as AdhexPharma.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
AdhexPharma social profiles
Digital presenceAdhexPharma compliance and trust
Trust signalCompliance6 records
AdhexPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
AdhexPharma leadership team
Management profileNumber of profiles
Profiles5 records
AdhexPharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
AdhexPharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AdhexPharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AdhexPharma
What does AdhexPharma do?
AdhexPharma is a full-service pharmaceutical CDMO specializing in the development and manufacturing of transdermal patches and oral films. The company provides end-to-end services from drug concept to market, including contract development, cGMP-compliant contract manufacturing, analytical services, and licensing of proprietary drug delivery technologies (Transfilm®, Rapidfilm®, Mucofilm®) and finished products (Nicopatchlib®, Rivendo®, Zeqmelit®). AdhexPharma serves both blue-chip pharmaceutical companies and innovative start-ups, manufacturing approximately 180 million units annually across 8 approved products.
Is AdhexPharma a public or private company?
AdhexPharma is a private company. It is classified as corporate owned and is currently operating.
When was AdhexPharma founded?
AdhexPharma was founded in 2007. It employs 51 to 100 people.
Where is AdhexPharma based?
AdhexPharma is headquartered in Paris, France, in the Europe region.
How does AdhexPharma make money?
Four revenue lines are on record. Contract Development Services are the primary driver. The others are contract Manufacturing Services, licensing and analytical Services.
Who are AdhexPharma's main competitors?
Broad incumbents on record are Lonza Group, Recipharm and Catalent (Novo Holdings). Direct peers are Tapemark, Corium (Gurnet Point Capital), Noven Pharmaceuticals and LTS Lohmann Therapie-Systeme. Emerging players are Vektor Pharma, AavantiBio / Osmotica Pharmaceutical (oral film) and ARx Solutions.
Does AdhexPharma have an API?
No public API is recorded for AdhexPharma.
What industry is AdhexPharma in?
AdhexPharma's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.